Benzodiazepines: Their Use Either As Essential Medicines Or As Toxics Substances

Total Page:16

File Type:pdf, Size:1020Kb

Benzodiazepines: Their Use Either As Essential Medicines Or As Toxics Substances toxics Review Benzodiazepines: Their Use either as Essential Medicines or as Toxics Substances Edilma Sanabria 1 , Ronald Edgardo Cuenca 1, Miguel Ángel Esteso 2,3 and Mauricio Maldonado 4,* 1 Grupo GICRIM, Programa de Investigación Criminal, Universidad Manuela Beltrán, Avenida Circunvalar No. 60-00, 111321 Bogotá, Colombia; [email protected] (E.S.); [email protected] (R.E.C.) 2 Universidad Católica Santa Teresa de Jesús de Ávila, Calle los Canteros s/n, 05005 Ávila, Spain; [email protected] 3 U.D. Química Física, Universidad de Alcalá, 28805 Alcalá de Henares, Spain 4 Departamento de Química, Facultad de Ciencias, Universidad Nacional de Colombia, Sede Bogotá, Cr. 30 No. 45-03, 111321 Bogotá, Colombia * Correspondence: [email protected] Abstract: This review highlights the nature, characteristics, properties, pharmacological differences between different types of benzodiazepines, the mechanism of action in the central nervous system, and the degradation of benzodiazepines. In the end, the efforts to reduce the benzodiazepines’ adverse effects are shown and a reflection is made on the responsible uses of these medications. Keywords: benzodiazepines; medical uses; toxicology 1. Introduction According to the World Health Organization (WHO), benzodiazepines are essential medicines used in the treatment of many clinical disorders, including different kinds Citation: Sanabria, E.; Cuenca, R.E.; of epileptic attacks, panic, phobias, depression, excitation, aggressiveness, anxiety, and Esteso, M.Á.; Maldonado, M. insomnia, among others. Fast starting of action, efficiency, a minor number of collateral Benzodiazepines: Their Use either as effects, and minimum acute toxicity are some of the advantages of using these medicines. Essential Medicines or as Toxics However, these can also show serious adverse effects when they are used improperly. Some Substances. Toxics 2021, 9, 25. examples of this are: consumption times longer than prescribed; when they are consumed https://doi.org/10.3390/toxics9020025 mixed with other stimulants substances like Opium; consumption of chemically modified benzodiazepines which have not been approved as medicaments; overdose; if during the Received: 6 January 2021 Accepted: 19 January 2021 treatment both driving and heavy machinery handling is not restricted; and, used for Published: 1 February 2021 criminal purposes, when they are administered masked in drinks or food in order to steal or sexually abuse victims. Publisher’s Note: MDPI stays neutral 2. Benzodiazepines with regard to jurisdictional claims in published maps and institutional affil- The Benzodiazepines (BDZs) are a group of components that receive their name iations. because in their chemical structure have a benzene ring joined to other seven-members heterocyclic ring called Diazepine (Figure1). There is a wide range of medicines that belong to these types of substances. The type of BDZ depends on the component present in the basic nucleus of the compound. As an Copyright: © 2021 by the authors. example of it, Figure2 shows several BDZ structures, in which the termination, lam, pam, Licensee MDPI, Basel, Switzerland. etc., indicate which is its active principle. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Toxics 2021, 9, 25. https://doi.org/10.3390/toxics9020025 https://www.mdpi.com/journal/toxics Toxics 2021, 9, x FOR PEER REVIEW 19 of 19 R1 R2 Toxics 2021, 9, 25 N 2 of 18 Toxics 2021, 9, x FOR PEER REVIEW 19 of 19 R3 R7 N R1 R2 R2' N R3 R7 N Figure 1. Benzodiazepines basic structure. R2' There is a wide range of medicines that belong to these types of substances. The type of BDZ depends on the component present in the basic nucleus of the compound. As an example of it, Figure 2 shows several BDZ structures, in which the termination, lam, pam, Figureetc., indicate 1. Benzodiazepines which is its basic active structure. principle. Figure 1. Benzodiazepines basic structure. N There is a wideO range of medicinesN that belongH toO these types of substances.H O The type of BDZ dependsN on the componentN present in theN basic nucleusO of the compound.N As an example of it, Figure 2 shows several BDZ structures, in which the termination, lam,O pam,H etc.,Cl indicate whichN Clis its active principle.N Cl N OH Cl N Cl N O N H O H O N N N O N Diazepam Alprazolam Clorazepate Lorazepam OH Cl F3C N Cl N Cl NN OH Cl N O O N Cl O N N N N Cl DiazepamN AlprazolamN Cl ClorazepateN Cl LorazepamN O Cl F3C N O O N O N N N N Halazepam Clobazam Triazolam Prazepam Cl N N Cl N Cl N FigureFigure 2. 2.Chemical Chemical structures structures of of some some benzodiazepines. benzodiazepines. O Cl 3. Synthesis of Benzodiazepines 3. Synthesis of Benzodiazepines Within the BDZs group, several families of these compounds can be found differing Within the BDZs group, several families of these compounds can be found differing in the positionHalazepam and presenceClobazam of functional groups. Triazolam Some of the Prazepam great importance are 1,4- benzodiazepines,in the position and 1,5-benzodiazepines, presence of functional 1,4-benzodiazepines-2-ones, groups. Some of the andgreat 1,4-benzodiazepines- importance are 1,4- 3-ones.Figurebenzodiazepines, 2. The Chemical synthesis structures 1,5-benzodiazepines, of 1,5-benzodiazepines of some benzodiazepines. 1,4-benzodiazepines-2-ones, includes the reactions of phenylendiamines and 1,4-benzodiaze- with ketonespines-3-ones. in the presenceThe synthesis of catalysts of 1,5-benzodiazepines [1–4] by condensation includes with theα, reactionsβ-unsaturated of phenylendia- carbonyl compounds3.mines Synthesis with [ 5 ketonesof]. TheBenzodiazepines reactions in the presence can also beof carriedcatalysts out [1–4] under by solvent-free condensation conditions with α, [ 6β,7-unsatu-] or by rated carbonyl compounds [5]. The reactions can also be carried out under solvent-free meansWithin of procedures the BDZs under group, microwave several families conditions of these [8,9]. compounds can be found differing conditions [6,7] or by means of procedures under microwave conditions [8,9]. in theMethods position for and preparing presence 1,4-benzodiazepineof functional groups. derivatives Some of the include great importance an aromatic are elec- 1,4- Methods for preparing 1,4-benzodiazepine derivatives include an aromatic electro- trophilicbenzodiazepines, substitution 1,5-benzodiazepines, from N-substituted anilines1,4-benzodiazepines-2-ones, [10]. It is also possible and via 1,4-benzodiaze- a condensation philic substitution from N-substituted anilines [10]. It is also possible via a condensation reactionpines-3-ones. between Theo synthesis-substituted of 1,5-benzodiazepines benzylamines with activatedincludes the aziridines reactions by of ring-opening phenylendia- reaction between o-substituted benzylamines with activated aziridines by ring-opening reactionsmines with [11 ketones–13], among in the others. presence 1,4-Benzodiazepin-3-ones of catalysts [1–4] by condensation are synthesized with α by, β the-unsatu- con- reactions [11–13], among others. 1,4-Benzodiazepin-3-ones are synthesized by the conden- densationrated carbonyl of 2-bromobenzylamines compounds [5]. The withreactions amino can acids also [ 14be], carried as well out as byunder intramolecular solvent-free sation of 2-bromobenzylamines with amino acids [14], as well as by intramolecular nucle- nucleophylicconditions [6,7] aromatic or by substitutionmeans of proced [15]; otherures under alternate microwave methods conditions include cyclization [8,9]. process ophylic aromatic substitution [15]; other alternate methods include cyclization process by by UgiMethods reaction for [16 preparing,17]. The synthesis 1,4-benzodiazepine of 1,4-benzodiazepin-2-ones derivatives include includes an aromatic the previous electro- synthesisphilic substitution of the intermediate from N-substituted amino-ketone anilines [18]. Moreover,[10]. It is also cyclization possible processes via a condensation involving anreaction Ugi reaction between as o a-substituted first step [ 19benzylamines,20]. Finally, with other acti methodsvated aziridines include the by cascadering-opening cou- pling/ condensation process of 2-bromobenzylamines with amino acids [21] and Buchwald reactions [11–13], among others. 1,4-Benzodiazepin-3-ones are synthesized by the conden- reaction [22] (Figure3). sation of 2-bromobenzylamines with amino acids [14], as well as by intramolecular nucle- ophylic aromatic substitution [15]; other alternate methods include cyclization process by Toxics 2021, 9, x FOR PEER REVIEW 19 of 19 Ugi reaction [16,17]. The synthesis of 1,4-benzodiazepin-2-ones includes the previous syn- thesis of the intermediate amino-ketone [18]. Moreover, cyclization processes involving Toxics 2021, 9, 25 an Ugi reaction as a first step [19,20]. Finally, other methods include the cascade coupling/3 of 18 condensation process of 2-bromobenzylamines with amino acids [21] and Buchwald reac- tion [22] (Figure 3). FigureFigure 3. 3.Some Some synthesis synthesis routes routes toward toward benzodiazepines. benzodiazepines. 4.4. Benzodiazepines Benzodiazepines Action Action Mechanism Mechanism on on the the Central Central Nervous Nervous System System DueDue to to its its high high solubility solubility in in lipids, lipids, BDZ BDZ can can penetrate penetrate the the brain brain and and cause cause rapid rapid and and effectiveeffective
Recommended publications
  • Diazepam - Alcohol Withdrawal
    Diazepam - alcohol withdrawal Why have I been prescribed diazepam? If a person stops drinking alcohol after a time of drinking too much they can experience withdrawal effects. These include “the shakes”, sweating, having fits, seeing things which are not there (hallucinations) and feeling anxious and low in mood. They can feel wound up and find it difficult to sleep. These withdrawal effects can be very uncomfortable and in extreme cases can be dangerous if they persist into “DTs” (delirium tremens). Diazepam is used to help reduce these withdrawal symptoms. It relieves anxiety and tension and aids sleep. Diazepam can also prevent fits. It controls the withdrawal symptoms until the body is free of alcohol and has settled down. This usually takes three to seven days from the time you stop drinking. What exactly is diazepam? Diazepam is a benzodiazepine. This group of medicines is also called anxiolytics or minor tranquillisers. Diazepam has many uses. It can be used to reduce symptoms of anxiety and insomnia, as well as to help people come off alcohol. Diazepam should only be prescribed and taken as a short course. Is diazepam safe to take? Diazepam is safe to take for a short period of time, but it doesn’t suit everyone. Below are a few conditions where diazepam may be less suitable. If any of these apply to you please tell your doctor or key-worker. If you have depression or a mental illness If you have lung disease or breathing problems, or suffer from liver or kidney trouble If you take any other medicines or drugs, including those on prescription and bought from a chemist If you take illicit drugs bought “on the street” If you are pregnant or breast-feeding What is the usual dose of diazepam? The dose of diazepam will usually be started at 10-20mg four times a day.
    [Show full text]
  • What Is Diazepam?
    Diazepam (Di-a-ze-pam) Valium™ Patient Name: ___________________________________ Date: _____________________________________________ Doctor Name: ___________________________________ Emergency Number: ________________________________ Pharmacy: _____________________________________ Number: __________________________________________ What is Diazepam? • Diazepam is a medicine approved by the Food and Drug Administration to treat all types of seizures, including absence, myoclonic, atonic (drop attacks), partial seizures and seizures associated with Lennox-Gastaut syndrome. • It is most often used together with another antiepileptic drug. It is also used in emergency situations involving seizures. It may also be used for other conditions as well as seizures, such as anxiety. • The drug is quickly absorbed after taking it by mouth and it reaches its highest amount in the body in 1-2 hours. A rectal form of the medicine called diastat is also available. Important questions to ask your doctor: • Why am I being given this medicine? _________________________________________________________________ • What amount should I be taking? ____________________________________________________________________ What does this drug look like and how should I take it? There are several brands and generic forms of the medicine. The brand name Valium is shown below at the 0.5 mg pill, the 1 mg pill and the 2 mg pill and the generic form lorazepam at 1 mg pill is also shown. 10 mg diazepam 10 mg diazepam 2 mg diazepam 10 mg diazepam 5 mg diazepam 2 mg diazepam 5 mg diazepam 2 mg diazepam 10 mg Valium 5 mg Valium 2 mg Valium © 2010 epilepsy.com A service of the Epilepsy Foundation Diazepam (Di-a-ze-pam) Valium™ Frequently Asked Questions: How do I take Diazepam? To use the tablet form: chew tablets and swallow or swallow the tablet whole.
    [Show full text]
  • Uso Adecuado De BZD En Insomnio Y Ansiedad.Pdf
    Vol. 6 Nº 1 · OCTUBRE 2014 BOLETÍN CANARIO DE USO RACIONAL DEL MEDICAMENTO DEL SCS Uso adecuado de BENZODIAZEPINAS en insomnio y ansiedad. SUMARIO PERFIL FARMACOLÓGICO DE LAS BZD (Tabla 1). - INTRODUCCIÓN 1 - PERFIL FARMACOLÓGICO DE LAS BENZODIAZEPINAS 1 No todas las BZD son iguales, ni tienen las mismas indicaciones. - BENZODIAZEPINAS EN EL INSOMNIO 2 Conocer algunos aspectos sobre su perfil farmacológico es esencial para realizar una prescripción adecuada y segura. - BENZODIAZEPINAS EN LA ANSIEDAD 4 - RECOMENDACIONES PARA SUSPENDER 5 Por lo general las BZD se absorben muy bien por vía oral, mientras TRATAMIENTOS CON BZD que la vía intramuscular presenta una absorción lenta e irregular, por - BIBLIOGRAFÍA 7 lo que no suele ser muy recomendada. En situaciones de emergencia (convulsiones) es preferible utilizar la vía endovenosa. INTRODUCCIÓN Inicio de acción y vida media: el inicio de acción es distinto según el principio activo y constituye un criterio fundamental en la selección de Las benzodiazepinas (BZD) son psicofármacos que actúan aumentan- las BZD. Puede ser: de inicio rápido (0,5-1 h), de utilidad en el insomnio do la acción del ácido gammaaminobutírico (GABA), principal neuro- de conciliación y en crisis de ansiedad; de inicio intermedio (1-3 h) o transmisor inhibidor del sistema nervioso central. Tienen indicaciones de inicio lento (> 3 h), preferibles en insomnio de mantenimiento o terapéuticas diversas, y auque su uso más habitual es en el tratamien- despertar precoz y en la ansiedad generalizada. to de la ansiedad e insomnio, también se utilizan en la inducción a la anestesia, en el tratamiento de las crisis comiciales, en el síndrome La vida media de las BZD es otro de los criterios de selección y puede 5 de abstinencia alcohólica, como tratamiento coadyuvante de de dolor ser : corta (< 6 h); intermedia (6-24 h) y larga (> 24 h).
    [Show full text]
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW
    Guideline Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW Summary To provide the most up-to-date knowledge and current level of best practice for the treatment of withdrawal from alcohol and other drugs such as heroin, and other opioids, benzodiazepines, cannabis and psychostimulants. Document type Guideline Document number GL2008_011 Publication date 04 July 2008 Author branch Centre for Alcohol and Other Drugs Branch contact (02) 9424 5938 Review date 18 April 2018 Policy manual Not applicable File number 04/2766 Previous reference N/A Status Active Functional group Clinical/Patient Services - Pharmaceutical, Medical Treatment Population Health - Pharmaceutical Applies to Area Health Services/Chief Executive Governed Statutory Health Corporation, Board Governed Statutory Health Corporations, Affiliated Health Organisations, Affiliated Health Organisations - Declared Distributed to Public Health System, Ministry of Health, Public Hospitals Audience All groups of health care workers;particularly prescribers of opioid treatments Secretary, NSW Health Guideline Ministry of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/ space space Drug and Alcohol Withdrawal Clinical Practice Guidelines - NSW space Document Number GL2008_011 Publication date 04-Jul-2008 Functional Sub group Clinical/ Patient Services - Pharmaceutical Clinical/ Patient Services - Medical Treatment Population Health - Pharmaceutical
    [Show full text]
  • Understanding Benzodiazephine Use, Abuse, and Detection
    Siemens Healthcare Diagnostics, the leading clinical diagnostics company, is committed to providing clinicians with the vital information they need for the accurate diagnosis, treatment and monitoring of patients. Our comprehensive portfolio of performance-driven systems, unmatched menu offering and IT solutions, in conjunction with highly responsive service, is designed to streamline workflow, enhance operational efficiency and support improved patient care. Syva, EMIT, EMIT II, EMIT d.a.u., and all associated marks are trademarks of General Siemens Healthcare Diagnostics Inc. All Drugs other trademarks and brands are the Global Division property of their respective owners. of Abuse Siemens Healthcare Product availability may vary from Diagnostics Inc. country to country and is subject 1717 Deerfield Road to varying regulatory requirements. Deerfield, IL 60015-0778 Please contact your local USA representative for availability. www.siemens.com/diagnostics Siemens Global Headquarters Global Siemens Healthcare Headquarters Siemens AG Understanding Wittelsbacherplatz 2 Siemens AG 80333 Muenchen Healthcare Sector Germany Henkestrasse 127 Benzodiazephine Use, 91052 Erlangen Germany Abuse, and Detection Telephone: +49 9131 84 - 0 www.siemens.com/healthcare www.usa.siemens.com/diagnostics Answers for life. Order No. A91DX-0701526-UC1-4A00 | Printed in USA | © 2009 Siemens Healthcare Diagnostics Inc. Syva has been R1 R2 a leading developer N and manufacturer of AB R3 X N drugs-of-abuse tests R4 for more than 30 years. R2 C Now part of Siemens Healthcare ® Diagnostics, Syva boasts a long and Benzodiazepines have as their basic chemical structure successful track record in drugs-of-abuse a benzene ring fused to a seven-membered diazepine ring. testing, and leads the industry in the All important benzodiazepines contain a 5-aryl substituent ring (ring C) and a 1,4–diazepine ring.
    [Show full text]
  • Risk Based Requirements for Medicines Handling
    Risk based requirements for medicines handling Including requirements for Schedule 4 Restricted medicines Contents 1. Introduction 2 2. Summary of roles and responsibilities 3 3. Schedule 4 Restricted medicines 4 4. Medicines acquisition 4 5. Storage of medicines, including control of access to storage 4 5.1. Staff access to medicines storage areas 5 5.2. Storage of S4R medicines 5 5.3. Storage of S4R medicines for medical emergencies 6 5.4. Access to storage for S4R and S8 medicines 6 5.5. Pharmacy Department access, including after hours 7 5.6. After-hours access to S8 medicines in the Pharmacy Department 7 5.7. Storage of nitrous oxide 8 5.8. Management of patients’ own medicines 8 6. Distribution of medicines 9 6.1. Distribution outside Pharmacy Department operating hours 10 6.2. Distribution of S4R and S8 medicines 10 7. Administration of medicines to patients 11 7.1. Self-administration of scheduled medicines by patients 11 7.2. Administration of S8 medicines 11 8. Supply of medicines to patients 12 8.1. Supply of scheduled medicines to patients by health professionals other than pharmacists 12 9. Record keeping 13 9.1. General record keeping requirements for S4R medicines 13 9.2. Management of the distribution and archiving of S8 registers 14 9.3. Inventories of S4R medicines 14 9.4. Inventories of S8 medicines 15 10. Destruction and discards of S4R and S8 medicines 15 11. Management of oral liquid S4R and S8 medicines 16 12. Cannabis based products 17 13. Management of opioid pharmacotherapy 18 14.
    [Show full text]
  • Retention Behaviour of Some Benzodiazepines in Solid-Phase Extraction Using Modified Silica Adsorbents Having Various Hydrophobicities
    ACADEMIA ROMÂNĂ Rev. Roum. Chim., Revue Roumaine de Chimie 2015, 60(9), 891-898 http://web.icf.ro/rrch/ RETENTION BEHAVIOUR OF SOME BENZODIAZEPINES IN SOLID-PHASE EXTRACTION USING MODIFIED SILICA ADSORBENTS HAVING VARIOUS HYDROPHOBICITIES Elena BACALUM,a Mihaela CHEREGIb,* and Victor DAVIDb,* a Research Institute from University of Bucharest – ICUB, 36-46 M. Kogalniceanu Blvd., Bucharest, 050107, Roumania b University of Bucharest, Faculty of Chemistry, Department of Analytical Chemistry, 90 Panduri Ave, Bucharest – 050663, Roumania Received April 6, 2015 The retention properties of six benzodiazepines (alprazolam, bromazepam, diazepam, flunitrazepam, medazepam, and nitrazepam) on four different solid phase extraction silica 1.0 adsorbents with various hydrophobicities (octadecylsilica, octylsilica, phenylsilica, and cyanopropylsilica) were 0.8 H O investigated. The breakthrough curves showed a significant N retention of these compounds on octadecylsilica, octylsilica, 0.6 Br N phenylsilica, excepting alprazolam that has a poor retention on 0 C/C N octadecylsilica. These results can be explained by the 0.4 PHENYL CN hydrophobic character of studied benzodiazepines (octanol- C18 0.2 C8 Bromazepam water partition constant, log Kow, being situated within the interval 1.90-4.45). A poor retention on cyanopropylsilica was 0.0 observed for all studied compounds indicating that π-π and 0 102030405060708090100 Volume (mL) polar intermolecular interactions have a less significant role in their retention on this adsorbent. Generally, the breakthrough
    [Show full text]
  • Withdrawing Benzodiazepines in Primary Care
    PC\/ICU/ ADTiriC • CNS Drugs 2009,-23(1): 19-34 KtVltW MKIIWLC 1172-7047/I»/O(X)1«119/S4W5/C1 © 2009 Adis Dato Intocmation BV. All rights reserved. Withdrawing Benzodiazepines in Primary Care Malcolm Luder} Andre Tylee^ and ]ohn Donoghue^ 1 Institute of Psychiatry, King's College London, London, England 2 John Moores University, Liverpool, Scotland Contents Abstract ' 19 1. Benzodiazepine Usage 22 2. Interventions 23 2.1 Simple interventions 23 2.2 Piiarmacoiogicai interventions 25 2.3 Psychoiogical Interventions 26 2.4 Meta-Anaiysis ot Various interventions 27 3. Outcomes 28 4. Practicai Issues 29 5. Otiier Medications 30 5.1 Antidepressants 30 5.2 Symptomatic Treatments 30 6. Conciusions 31 Abstract The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinua- tion is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addic- tion have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescdbers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discon- tinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescdbers.
    [Show full text]
  • Test Update Immediate Action Notification
    Effective Date: Monday, April 27, 2020 Test Updates Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, April 27, 2020 Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS Labs 200 Welsh Rd. Horsham, PA 19044-2208 [email protected] Page 1 of 6 Effective Date: Monday, April 27, 2020 Test Updates Test Test Name Test Method / Specimen Stability Scope Units Reference Discontinue Code Name CPT Code Req. Comments Designer Benzodiazepines (Qualitative), 0570U • Urine (Forensic) Designer Benzodiazepines Confirmation 52487U • (Qualitative), Urine Designer Benzodiazepines Confirmation, 52487B • Blood Designer Benzodiazepines Confirmation, 52487SP • Serum/Plasma Designer Benzodiazepines, Blood 0570B • (Forensic) Designer Benzodiazepines, 0570SP • Serum/Plasma (Forensic) NMS Labs 200 Welsh Rd.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Dynamic Regulation of the GABAA Receptor Function by Redox Mechanisms S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2016/07/20/mol.116.105205.DC1 1521-0111/90/3/326–333$25.00 http://dx.doi.org/10.1124/mol.116.105205 MOLECULAR PHARMACOLOGY Mol Pharmacol 90:326–333, September 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics MINIREVIEW—A LATIN AMERICAN PERSPECTIVE ON ION CHANNELS Dynamic Regulation of the GABAA Receptor Function by Redox Mechanisms s Daniel J. Calvo and Andrea N. Beltrán González Laboratorio de Neurobiología Celular y Molecular, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Downloaded from ¨Dr. Héctor N. Torres¨ (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina (D.J.C., A.N.B.G.) Received May 15, 2016; accepted July 14, 2016 ABSTRACT molpharm.aspetjournals.org Oxidizing and reducing agents, which are currently involved normally present in neurons and glia or are endogenously in cell metabolism and signaling pathways, can regulate fast generated in these cells under physiologic states or during inhibitory neurotransmission mediated by GABA receptors in the oxidative stress (e.g., hydrogen peroxide, superoxide and hy- nervous system. A number of in vitro studies have shown that droxyl radicals, nitric oxide, ascorbic acid, and glutathione), diverse redox compounds, including redox metabolites and induce potentiating or inhibiting actions on different native and reactive oxygen and nitrogen species, modulate phasic and recombinant GABAA receptor subtypes. Based on these results, it tonic responses mediated by neuronal GABAA receptors through is thought that redox signaling might represent a homeostatic both presynaptic and postsynaptic mechanisms.
    [Show full text]